title: Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).
abstract: The Canadian Consensus Working Group has updated its evaluation of the literature pertaining to statin intolerance and adverse effects. This overview introduces a pragmatic definition of statin intolerance (goal-inhibiting statin intolerance) that emphasizes the effects of symptoms on achieving nationally vetted goals in patients fulfilling indications for lipid-lowering therapy and cardiovascular risk reduction. The Canadian Consensus Working Group provides a structured framework for avoiding, evaluating and managing goal-inhibiting statin intolerance. Particularly difficult practice situations are reviewed, including management in young and elderly individuals, and in athletes and labourers. Finally, targeted at specialty practitioners, more detailed analyses of specific but more unusual adverse effects ascribed to statins are updated including evidence regarding new-onset diabetes, cognitive dysfunction, cataracts, and the rare but important immune-mediated necrotizing myopathy.
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: mancini@mail.ubc.ca.
authors.forename: G B John
authors.initials: GB
authors.lastname: Mancini
authors.affiliation: McMaster University, Hamilton, Ontario, Canada.
authors.forename: Steven
authors.initials: S
authors.lastname: Baker
authors.affiliation: Laval University, Quebec City, Quebec, Canada.
authors.forename: Jean
authors.initials: J
authors.lastname: Bergeron
authors.affiliation: University of Toronto, Toronto, Ontario, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Fitchett
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jiri
authors.initials: J
authors.lastname: Frohlich
authors.affiliation: McGill University, Montreal, Quebec, Canada.
authors.forename: Jacques
authors.initials: J
authors.lastname: Genest
authors.affiliation: McMaster University, Hamilton, Ontario, Canada.
authors.forename: Milan
authors.initials: M
authors.lastname: Gupta
authors.affiliation: Schulich School of Medicine, London, Ontario, Canada.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hegele
authors.affiliation: University of Toronto, Toronto, Ontario, Canada.
authors.forename: Dominic
authors.initials: D
authors.lastname: Ng
authors.affiliation: University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Glen J
authors.initials: GJ
authors.lastname: Pearson
authors.affiliation: Schulich School of Medicine, London, Ontario, Canada.
authors.forename: Janet
authors.initials: J
authors.lastname: Pope
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: A Yashar
authors.initials: AY
authors.lastname: Tashakkor
mesh_terms: D001327:Autoimmune Diseases / Q000139:chemically induced / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002386:Cataract / Q000139:chemically induced / Q000517:prevention & control; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D009135:Muscular Diseases / Q000139:chemically induced / Q000517:prevention & control; D040242:Risk Reduction Behavior
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors